A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity

Completed

• Conditions: Apixaban; Obesity; Anticoagulant
• Interventions: Diagnostic Test: Anti Xa levels

• Registration Number: NCT03893591
• Lead Sponsor: HaEmek Medical Center, Israel

Brief Summary

A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-03-26
• Study First Submitted QC: 2019-03-26
• Study First Posted: 2019-03-28
• Study Start: 2019-05-06
• Primary Completion: 2020-02-29
• Study Completion: 2020-02-29
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-31
• Last Update Posted: 2020-04-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

• hospitalized Patients on Steady State level of Apixaban, based on the data given in the hospital ward . A level of Steady State is received within two days of treatment.

Exclusion Criteria

• Anasarca
• acute renal failure

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Body mass index below 35	Anti Xa levels	-
Body mass index 35 and above	Anti Xa levels	-

Primary Outcome Measures

Name	Time	Method
Anti Xa level of patients with atrial fibrillation and obesity while treatment of Apixaban.	6 month

Trial Locations

Locations (1)

HaEmek Medical Center; 🇮🇱 Afula, Israel